Reported about 22 hours ago
Moderna's stock dropped almost 17% after the company cut its 2025 revenue outlook by $1 billion, raising concerns among investors. The significant decline follows a breakdown from a pennant pattern and a worsening revenue landscape due to declining demand for Covid-19 treatments. Key support levels to monitor include $30 and $13, while resistance is noted around $57 and $68. With a substantial loss of value over the past year, investors are closely evaluating these critical price levels.
Source: YAHOO